News | Heart Failure | February 22, 2017

New RightSTEPS Educational Initiative to Drive Change in Clinician Prescribing Behavior for Chronic Heart Failure

Blended-learning initiative provides comprehensive education to empower clinicians to take the RightSTEPS to treat the right patients with the right drugs at the right dose at the right time

ACC, Haymarket Medical Education, HME, myCME, RightSTEPS initiative, prescribing behavior, chronic heart failure

February 22, 2017 — The American College of Cardiology (ACC), Haymarket Medical Education (HME) and myCME have joined forces to develop RightSTEPS: Optimizing Medical Therapy for Chronic Heart Failure. This long-term education initiative aims to help clinicians follow prescribing guidelines to reduce hospitalizations and readmissions and to improve patient outcomes to address the 75 percent of chronic heart failure (HF) patients who do not receive optimal doses of guideline-recommended drugs.

Launching in 2017, with additional education to be added regularly throughout the year, the program is overseen by leading experts in HF treatment, including Akshay S. Desai, M.D., MPH, FACC, director, heart failure disease management, Cardiovascular Division, Brigham and Women’s Hospital and associate professor of ,edicine, Harvard Medical School. The curriculum includes American College of Cardiology/American Heart Association guideline-driven medical therapy, and it enables clinicians to:

  • Learn via a dedicated online Cardiology Learning Center on myCME offering self-paced, personalized educational activities that are eligible for up to 16 continuing medical education (CME)/continuing nursing education (CNE) complimentary credits, including individualized treatments for various gender and racial/ethnic populations;
  • Practice during face-to-face live meetings at regional healthcare systems, with parallel sessions for patients and caregivers at Veterans Affairs hospitals; and
  • Perform and receive customized online coaching that qualifies as a Centers for Medicare & Medicaid Services (CMS) Quality Payment Program Improvement Activity under the new Merit-based Incentive Payment System (MIPS).

“Improving heart health is at the core of the ACC’s mission,” said Desai, ACC RightSTEPS chair and course director. “With RightSTEPS, medical professionals treating heart failure patients have easier access to the tools they need to make informed, guideline-driven decisions and provide their patients with the highest quality care.”

“Successful treatment of chronic HF depends on both medical knowledge and ongoing dialogue,” said Priya Wanchoo, M.D., medical director of myCME. “We’re pleased the education we develop with the ACC for RightSTEPS will have a dedicated home on myCME. We believe it will provide clinicians a support center for their efforts in providing optimal patient care.”

Supported by an independent educational grant from Novartis Pharmaceuticals Corporation, the curriculum is designed for the range of clinicians who provide care for patients with chronic HF, including cardiologists, internists, primary care physicians, nurses, nurse practitioners and physician assistants. To further close the circle and improve performance, it includes education geared for patients with chronic HF and their caregivers.

For more information:

Related Content

News | Pharmaceuticals| September 12, 2017
September 12, 2017 — Inclisiran lowers low-density lipoprotein (LDL, or “bad”) cholesterol for up to one year in pati
New FOURIER Analysis Examines How Low Cholesterol Can Safely Go
News | ESC| September 12, 2017
September 12, 2017 — Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressive
CANTOS Study Shows Reducing Inflammation Cuts Cardiovascular Disease, Lung Cancer Risk
News | ESC| September 12, 2017
September 12, 2017 — The IL-1β inhibitor canakinumab lowers the risk of cardiovascular disease and lung cancer risk b
COMPASS Trial Shows Rivaroxaban With Aspirin Improves Stable Cardiovascular Disease
Feature | Antiplatelet and Anticoagulation Therapies| September 12, 2017
September 12, 2017 — Rivaroxaban plus aspirin improves survival and reduces stroke and heart attack in patients with
Merck Announces Results of REVEAL Outcomes Study of Anacetrapib
News | Pharmaceuticals| September 11, 2017
Merck and researchers in the Clinical Trial Service Unit at the University of Oxford announced the publication and...
Heart Failure Patients, Clinicians Have Differing Perceptions of Risk Level
News | Heart Failure| September 06, 2017
September 6, 2017 — Physicians identified a majority of patients with advanced...
Israeli Hospital Completes First Implant of CORolla Heart Failure Device
News | Heart Failure| September 05, 2017
Rambam Hospital in Haifa, Israel, recently became the first to use the CORolla device from Israeli start-up company...
Abbott Receives FDA Approval for HeartMate 3 Left Ventricular Assist System
Technology | Ventricular Assist Devices (VAD)| August 29, 2017
Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev HeartMate 3 Left...
Sponsored Content | Videos | Cardiovascular Ultrasound| August 28, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Real-World Analysis Compares Safety, Effectiveness of Apixaban Versus Warfarin
News | Antiplatelet and Anticoagulation Therapies| August 28, 2017
August 28, 2017 — Bristol-Myers Squibb Company and Pfizer Inc.
Overlay Init